^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:IPN60210 (SETD2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Epizyme Press Release
    Title:

    Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414

    Published date:
    11/04/2021
    Excerpt:
    Epizyme, Inc...today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to EZM0414, the Company’s novel, first-in-class, oral SETD2 inhibitor, as an investigational agent for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).